AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2017
Nov 15, 2017
29828_dirs_2017-11-15_41676a42-bc59-43b9-816a-7e3fbf61e360.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2017-11-13
Reporting Person: MILLIGAN JOHN F (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-13 | Common Stock | M | 220000 | $21.575 | Acquired | 1385924 | Direct |
| 2017-11-13 | Common Stock | S | 220000 | $72.8849 | Disposed | 1165924 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-13 | Non-qualified Stock Option (Right to Buy) | $21.575 | M | 220000 | Disposed | 2018-01-30 | Common Stock (220000) | Direct |
Footnotes
F1: The exercise and sale transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: Sale prices reported for the transactions reported here range from $72.5201 to $73.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the Issuer or its shareowners upon request.
F3: The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013.